Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease.

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Acronyms TUBERCULOSIS-017
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Feb 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top